FDA wants investigation into Avandia conflict: report

NEW YORK Sat Jul 24, 2010 4:11am IST

Related Topics

Stocks

   

NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.

David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.

Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.

FILED UNDER:
  • Most Popular
  • Most Shared
Biotech Leap

Biotech Leap

World's top drugmaker Novartis takes aim at tech  Full Article 

Bird Flu

Bird Flu

Bird flu found in UK, Netherlands but authorities say little risk to humans  Full Article 

Drug Abuse

Drug Abuse

‘Tweens’ most likely to misuse over-the-counter meds.  Full Article 

Nutrition Value

Nutrition Value

School lunches may be better than lunch packed at home.  Full Article 

Smoking Problem

Smoking Problem

U.S. youth smoking, increased use of e-cigarettes a worry: CDC.  Full Article 

No Progress

No Progress

Progress on eliminating measles has stalled, WHO warns.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage